high-value compounds and pharmaceuticals form microalgae · uts cricos provider code: 00099f...
TRANSCRIPT
UTS CRICOS PROVIDER CODE: 00099F
UTS:SCIENCE
HIGH-VALUE COMPOUNDS AND
PHARMACEUTICALS
FROM MICROALGAE
c3.uts.edu.au
Algal Biosystems and Biotechnology Climate Change Cluster (C3) - UTS
Dr. Michele Fabris
Science-Industry Connect - July 20th 2016
How to turn this….
c3.uts.edu.au
www.greenovation.com ….into this?
Algae Biotech applications Algae as bio-factories UTS-C3 Algal Biosystems and Biotech group Our research focus Current projects …How to engage with us?
Outline
c3.uts.edu.au
Eukaryotic, photosynthetic microorganisms Enormous diversity Genomics, transcriptomics & metabolomics resources are gradually unveiling their traits Massive Biotechnology Opportunity
Algae
c3.uts.edu.au
© Dr. M. Huysman http://web.mst.edu
www.algae-mart.com
Biofuels Anaerobic digestion Aquaculture
Algae’s industrial potential
c3.uts.edu.au
PUFAs (omega 3) Pigments
Algae’s industrial potential
c3.uts.edu.au
Secondary metabolites Phenols Terpenoids Flavonoids …
Using GM technology and synthetic biology Bulk chemicals High-value metabolites Recombinant proteins
Algae’s industrial potential
c3.uts.edu.au
Hempel et al., 2012
Poly-3-hydroxybutyrate (PHB)
Interferon α-2A
Nutraceuticals, therapeutics and cosmetics • Huge diversity – more than 200.000 species • Natural products - only minimally characterised • Microbes – use of biomass is maximised • Fast growth - high densities • Extremely inexpensive medium requirements • Resistant to stresses • Scalable in contained systems • Genetic engineering is feasible
Cell-sized algal bio-factories
c3.uts.edu.au
Recombinant therapeutics from algae
c3.uts.edu.au
Algae Very low Short/medium Very high (Very) high Low risk
Adapted from
Ma, et al, N
at Rev G
en 2003
Ideal organisms for synthetic biology applications
Algal strains are natural isolates, not fit to thrive in highly artificial environment (industrial settings) Algal genetic toolbox is in an early stage Lack of high-throughput pipelines
Bio-therapeutics form algae - research challenges
c3.uts.edu.au
Optimization of cultivation conditions Optimization of organism
Synthetic biology and molecular genetics
Methods development
Cross-disciplinary Top-level instrumental set-up Areas of application: • Aquaculture • Biofuels • Nutraceuticals • Cosmetics • Bio-therapeutics
Algal Biosystems and Biotechnology
c3.uts.edu.au
Molecular biology, genetic engineering, bioinformatics and synthetic biology Cultivation strategies Downstream processing, purification and quality control
GE-UTS Algal Bio-Factory - Research focus
c3.uts.edu.au
• Molecular toolbox for efficient and controlled gene expression
• Secondary metabolites
• Cultivation-production strategies
• Novel species as expression platforms
• High-throughput algal transformation & screening
Our algal strains
C. reinhardtii, N. gaditana, N. oceanica, … more to come
Current Projects
c3.uts.edu.au
GE UTS Algal bio-factory research
program
Our products:
Human membrane proteins of the CLIC family
Interferon alpha 2A
Anti-inflammatory peptides
Future: antibodies?anti-cancer drugs? vaccines?
Algae Biotech applications Algae as bio-factories UTS-C3 Algal Biosystems and Biotech group Our research focus …How to engage with us?
Summary
c3.uts.edu.au
We work on fundamental biological questions that have an impact in industrial and pharmaceutical applications ….amongst others. We welcome industry engagement to help direct our research and provide future challenges. Get in touch with us, and let us help you find your ideal algae!
Collaborations
c3.uts.edu.au
Advanced Algal Innovation Network Membership Sponsorship Engagement
ACKNOWLEDGMENTS Prof. Peter Ralph Dr. Audrey Commault Dr. Mathieu Pernice Dr. Brenton Hamdorf Jack Adriaans Alex-Lincoln Dodgson Dr. Pavlina Sasheva Dr. Bojan Tamburic Dr. Christian Evenhuis Dr. Milan Szabo Algal Biosystems & Biotech group Tech-staff
Prof. Peter Ralph Algal Biosystems and Biotechnology Group Leader C3 Executive Director [email protected]
Dr. Michele Fabris C3 Research Associate [email protected]
GET IN TOUCH WITH US
Dr. Brenton Hamdorf C3 Industry Engagement Manager [email protected]
IN THE AUDIENCE TODAY